Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
DNP – Die Neurologie & Psychiatrie
Erschienen in: DNP - Der Neurologe & Psychiater 3/2014

07.03.2014 | Fortbildung

Ursache bleibt häufig unklar

Juveniler Schlaganfall

verfasst von: Prof. Dr. med. Klaus Jahn, Dr.med. univ. Maximilian Einhäupl

Erschienen in: DNP – Die Neurologie & Psychiatrie | Ausgabe 3/2014

Einloggen, um Zugang zu erhalten

Zusammenfassung

Bei den meisten jugendlichen Schlaganfällen handelt es sich um kryptogene Ereignisse. Mit zunehmender Inzidenz kommt den Schlaganfall-Patienten im Alter von 15 bis 50 Jahren im klinischen Alltag eine steigende Bedeutung zu. Für den Neurologen in Klinik und Praxis stellt sich damit die Frage nach den Charakteristika des juvenilen Schlaganfalls und den daraus resultierenden Konsequenzen für Diagnostik, Therapie und Prophylaxe.
Literatur
1.
Feigin VL, Lawes CM, Bennett DA, Barker-Collo SL, Parag V. Worldwide stroke incidence and early case fatality reported in 56 population-based studies: a systematic review. Lancet Neurol. [Research Support, Non-U.S. Gov’t Review]. 2009;8(4):355–69.PubMedCrossRef
2.
Bejot Y, Daubail B, Jacquin A, Durier J, Osseby GV, Rouaud O, et al. Trends in the incidence of ischaemic stroke in young adults between 1985 and 2011: the Dijon Stroke Registry. J Neurol Neurosurg Psychiatry. 2013.
3.
Kissela BM, Khoury JC, Alwell K, Moomaw CJ, Woo D, Adeoye O, et al. Age at stroke: temporal trends in stroke incidence in a large, biracial population. Neurology. 2012;79(17):1781–7.PubMedCentralPubMedCrossRef
4.
George MG, Tong X, Kuklina EV, Labarthe DR. Trends in stroke hospitalizations and associated risk factors among children and young adults, 1995–2008. Ann Neurol. 2011;70(5):713–21.PubMedCrossRef
5.
Kolominsky-Rabas PL, Sarti C, Heuschmann PU, Graf C, Siemonsen S, Neundoerfer B, et al. A prospective community-based study of stroke in Germany—the Erlangen Stroke Project (ESPro): incidence and case fatality at 1, 3, and 12 months. Stroke. [Research Support, Non-U.S. Gov’t]. 1998;29(12):2501–6.PubMedCrossRef
6.
Groppo E, De] Gennaro R, Granieri G, Fazio P, Cesnik E, Granieri E, et al. Incidence and prognosis of stroke in young adults: a population-based study in Ferrara, Italy. Neurol Sci. [Research Support, Non-U.S. Gov’t]. 2012;33(1):53–8.PubMedCrossRef
7.
Marini C, Russo T, Felzani G. Incidence of stroke in young adults: a review. Stroke Res Treat. 2010;2011:535672.
8.
Leys D, Bandu L, Henon H, Lucas C, Mounier-Vehier F, Rondepierre P, et al. Clinical outcome in 287 consecutive young adults (15 to 45 years) with ischemic stroke. Neurology. [Research Support, Non-U.S. Gov’t]. 2002;59(1):26–33.PubMedCrossRef
9.
Adams HP, Jr., Bendixen BH, Kappelle LJ, Biller J, Love BB, Gordon DL, et al. Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment. Stroke. [Clinical Trial Multicenter Study Randomized Controlled Trial Research Support, U.S. Gov’t, P.H.S.]. 1993;24(1):35–41.
10.
Ferro JM, Massaro AR, Mas JL. Aetiological diagnosis of ischaemic stroke in young adults. Lancet Neurol. [Review]. 2010;9(11):1085–96.
11.
Putaala J, Metso AJ, Metso TM, Konkola N, Kraemer Y, Haapaniemi E, et al. Analysis of 1008 consecutive patients aged 15 to 49 with first-ever ischemic stroke: the Helsinki young stroke registry. Stroke. [Research Support, Non-U.S. Gov’t]. 2009;40(4):1195–203.
12.
Cerrato P, Grasso M, Imperiale D, Priano L, Baima C, Giraudo M, et al. Stroke in young patients: etiopathogenesis and risk factors in different age classes. Cerebrovasc Dis. 2004;18(2):154–9.PubMedCrossRef
13.
Varona JF, Bermejo F, Guerra JM, Molina JA. Long-term prognosis of ischemic stroke in young adults. Study of 272 cases. J Neurol. 2004;251(12):1507–14.
14.
Kolominsky-Rabas PL, Weber M, Gefeller O, Neundoerfer B, Heuschmann PU. Epidemiology of ischemic stroke subtypes according to TOAST criteria: incidence, recurrence, and long-term survival in ischemic stroke subtypes: a population-based study. Stroke. [Research Support, Non-U.S. Gov’t]. 2001;32(12):2735–40.PubMedCrossRef
15.
Marnane M, Duggan CA, Sheehan OC, Merwick A, Hannon N, Curtin D, et al. Stroke subtype classification to mechanism-specific and undetermined categories by TOAST, AS-C-O, and causative classification system: direct comparison in the North Dublin population stroke study. Stroke. [Research Support, Non-U.S. Gov’t]. 2010;41(8):1579–86.PubMedCrossRef
16.
Balci K, Utku U, Asil T, Celik Y. Ischemic stroke in young adults: risk factors, subtypes, and prognosis. Neurologist. 2011;17(1):16–20.PubMedCrossRef
17.
Manolescu BN, Oprea E, Farcasanu IC, Berteanu M, Cercasov C. Homocysteine and vitamin therapy in stroke prevention and treatment: a review. Acta Biochim Pol. [Review]. 2010;57(4):467–77.PubMed
18.
Marti-Carvajal AJ, Sola I, Lathyris D, Karakitsiou DE, Simancas-Racines D. Homocysteine-lowering interventions for preventing cardiovascular events. Cochrane Database Syst Rev. [Meta-Analysis Research Support, Non-U.S. Gov’t Review]. 2013;1:CD006612.
19.
Amarenco P, Labreuche J. Lipid management in the prevention of stroke: review and updated meta-analysis of statins for stroke prevention. Lancet Neurol. [Meta-Analysis Review]. 2009;8(5):453–63.CrossRef
20.
Putaala J, Haapaniemi E, Kaste M, Tatlisumak T. Statins after ischemic stroke of undetermined etiology in young adults. Neurology. [Research Support, Non-U.S. Gov’t]. 2011;77(5):426–30.CrossRef
21.
Lee VH, Brown RD, Jr., Mandrekar JN, Mokri B. Incidence and outcome of cervical artery dissection: a population-based study. Neurology. 2006;67(10):1809–12.PubMedCrossRef
22.
Debette S, Leys D. Cervical-artery dissections: predisposing factors, diagnosis, and outcome. Lancet Neurol. [Research Support, Non-U.S. Gov’t Review]. 2009;8(7):668–78.PubMedCrossRef
23.
Brandt T, Orberk E, Weber R, Werner I, Busse O, Muller BT, et al. Pathogenesis of cervical artery dissections: association with connective tissue abnormalities. Neurology. [Multicenter Study Research Support, Non-U.S. Gov’t]. 2001;57(1):24–30.PubMedCrossRef
24.
Lyrer P, Engelter S. Antithrombotic drugs for carotid artery dissection. Cochrane Database Syst Rev. [Meta-Analysis Review]. 2010(10):CD000255.
25.
Rich MW. Epidemiology of atrial fibrillation. J Interv Card Electrophysiol. [Research Support, N.I.H., Extramural Review]. 2009;25(1):3–8.PubMedCrossRef
26.
Cotter PE, Martin PJ, Ring L, Warburton EA, Belham M, Pugh PJ. Incidence of atrial fibrillation detected by implantable loop recorders in unexplained stroke. Neurology. 2013;80(17):1546–50.PubMedCrossRef
27.
Etgen T, Hochreiter M, Mundel M, Freudenberger T. Insertable cardiac event recorder in detection of atrial fibrillation after cryptogenic stroke: an audit report. Stroke. 2013;44(7):2007–9.PubMedCrossRef
28.
Davis D, Gregson J, Willeit P, Stephan B, Al-Shahi Salman R, Brayne C. Patent foramen ovale, ischemic stroke and migraine: systematic review and stratified meta-analysis of association studies. Neuroepidemiology. [Meta-Analysis Research Support}, Non-U.S. Gov’t Review]. 2013;40(1):56–67.
29.
Karttunen V, Hiltunen L, Rasi V, Vahtera E, Hillbom M. Factor V Leiden and prothrombin gene mutation may predispose to paradoxical embolism in subjects with patent foramen ovale. Blood Coagul Fibrinolysis. [Research Support, Non-U.S. Gov’t]. 2003;14(3):261–8.PubMed
30.
Pezzini A, Del Zotto E, Magoni M, Costa A, Archetti S, Grassi M, et al. Inherited thrombophilic disorders in young adults with ischemic stroke and patent foramen ovale. Stroke. 2003;34(1):28–33.
31.
Botto N, Spadoni I, Giusti S, Ait-Ali L, Sicari R, Andreassi MG. Prothrombotic mutations as risk factors for cryptogenic ischemic cerebrovascular events in young subjects with patent foramen ovale. Stroke. 2007;38(7):2070–3.PubMedCrossRef
32.
Consoli D, Paciaroni M, Aguggia M, Melis M, Malferrari G, Vidale S, et al. Prevalence of patent foramen ovale in ischemic stroke in Italy: the SISIFO study. Neurol Sci. 2014.
33.
Beitzke A, Schuchlenz H, Beitzke M, Gamillscheg A, Stein HI, Zartner P. [Interventional occlusion of foramen ovale and atrial septal defects after paradoxical embolism incidents]. Z Kardiol. [Comparative Study Evaluation Studies]. 2002;91(9):693–700.PubMedCrossRef
34.
Kitsios GD, Dahabreh IJ, Abu Dabrh AM, Thaler DE, Kent DM. Patent foramen ovale closure and medical treatments for secondary stroke prevention: a systematic review of observational and randomized evidence. Stroke. [Meta-Analysis Research Support, N.I.H., Extramural Review]. 2012;43(2):422–31.PubMedCentralPubMedCrossRef
35.
Riaz IB, Dhoble A, Mizyed A, Hsu CH, Husnain M, Lee JZ, et al. Transcatheter patent foramen ovale closure versus medical therapy for cryptogenic stroke: a meta-analysis of randomized clinical trials. BMC Cardiovasc Disord. 2013;13:116.PubMedCentralPubMedCrossRef
36.
Chen L, Luo S, Yan L, Zhao W. A systematic review of closure versus medical therapy for preventing recurrent stroke in patients with patent foramen ovale and cryptogenic stroke or transient ischemic attack. J Neurol Sci. 2013.
37.
Homma S, Sacco RL, Di Tullio MR, Sciacca RR, Mohr JP. Effect of medical treatment in stroke patients with patent foramen ovale: patent foramen ovale in Cryptogenic Stroke Study. Circulation. [Clinical Trial Multicenter Study Randomized Controlled Trial Research Support, U.S. Gov’t, P.H.S.]. 2002;105(22):2625–31.
38.
Pfefferkorn T, Bitterling H, Hufner K, Opherk C, Schewe S, Pfister HW, et al. Malignant hemispheric infarction in Takayasu arteritis. J Neurol. [Case Reports Letter]. 2008;255(9):1425–6.PubMedCrossRef
39.
Karassa FB, Matsagas MI, Schmidt WA, Ioannidis JP. Meta-analysis: test performance of ultrasonography for giant-cell arteritis. Ann Intern Med. [Meta-Analysis]. 2005;142(5):359–69.PubMedCrossRef
40.
Salvarani C, Brown RD, Jr., Hunder GG. Adult primary central nervous system vasculitis. Lancet. [Review]. 2012;380(9843):767–77.PubMedCrossRef
41.
Saam T, Habs M, Cyran CC, Grimm J, Pfefferkorn T, Schuller U, et al. [New aspects of MRI for diagnostics of large vessel vasculitis and primary angiitis of the central nervous system]. Radiologe. 2010;50(10):861–71.PubMedCrossRef
42.
Weber R, Goertler M, Benemann J, Diener HC, Weimar C. Prognosis after cryptogenic cerebral ischemia in patients with coagulopathies. Cerebrovasc Dis. [Multicenter Study Research Support, Non-U.S. Gov’t]. 2009;28(6):611–7.PubMedCrossRef
43.
Supanc V, Sonicki Z, Vukasovic I, Solter VV, Zavoreo I, Kes VB. The Role of Classic Risk Factors and Prothrombotic Factor Gene Mutations in Ischemic Stroke Risk Development in Young and Middle-Aged Individuals. J Stroke Cerebrovasc Dis. 2013.
44.
Dragoni F, Chiarotti F, Rosano G, Simioni P, Tormene D, Mazzucconi MG, et al. Thrombophilic screening in young patients (< 40 years) with idiopathic ischemic stroke: a controlled study. Thromb Res. 2011;127(2):85–90.PubMedCrossRef
45.
Longstreth WT, Jr., Rosendaal FR, Siscovick DS, Vos HL, Schwartz SM, Psaty BM, et al. Risk of stroke in young women and two prothrombotic mutations: factor V Leiden and prothrombin gene variant (G20210A). Stroke. [Research Support, Non-U.S. Gov’t Research Support, U.S. Gov’t, P.H.S.]. 1998;29(3):577–80.PubMedCrossRef
46.
Tuhrim S, Rand JH, Wu XX, Weinberger J, Horowitz DR, Goldman ME, et al. Elevated anticardiolipin antibody titer is a stroke risk factor in a multiethnic population independent of isotype or degree of positivity. Stroke. [Comparative Study Research Support, U.S. Gov’t, P.H.S.]. 1999;30(8):1561–5.PubMedCrossRef
47.
Anticardiolipin antibodies are an independent risk factor for first ischemic stroke. The Antiphospholipid Antibodies in Stroke Study (APASS) Group. Neurology. [Multicenter Study Research Support, Non-U.S. Gov’t]. 1993;43(10):2069-73.
48.
Hart RG, Miller VT, Coull BM, Bril V. Cerebral infarction associated with lupus anticoagulants-preliminary report. Stroke. [Case Reports]. 1984;15(1):114–8.PubMedCrossRef
49.
Levine SR, Brey RL, Tilley BC, Thompson JL, Sacco RL, Sciacca RR, et al. Antiphospholipid antibodies and subsequent thrombo-occlusive events in patients with ischemic stroke. Jama. [Clinical Trial Randomized Controlled Trial Research Support, U.S. Gov’t, P.H.S.]. 2004;291(5):576–84.PubMedCrossRef
50.
Lim W, Crowther MA, Eikelboom JW. Management of antiphospholipid antibody syndrome: a systematic review. Jama. [Review]. 2006;295(9):1050–7.PubMedCrossRef
51.
Crowther MA. Anticoagulant therapy for the thrombotic complications of the antiphospholipid antibody syndrome. Thromb Res. [Research Support, Non-U.S. Gov’t Review]. 2004;114(5-6):443–6.PubMedCrossRef
52.
Boehm I. Drug treatment-induced downregulation of antiphospholipid antibodies in PAPS. Clin Rheumatol. [Case Reports]. 2009;28(11):1347–8.PubMedCrossRef
53.
Chabriat H, Joutel A, Dichgans M, Tournier-Lasserve E, Bousser MG. Cadasil. Lancet Neurol. [Review]. 2009;8(7):643–53.
54.
Razvi SS, Davidson R, Bone I, Muir KW. The prevalence of cerebral autosomal dominant arteriopathy with subcortical infarcts and leucoencephalopathy (CADASIL) in the west of Scotland. J Neurol Neurosurg Psychiatry. [Research Support, Non-U.S. Gov’t]. 2005;76(5):739–41.PubMedCentralPubMedCrossRef
55.
Joutel A, Dodick DD, Parisi JE, Cecillon M, Tournier-Lasserve E, Bousser MG. De novo mutation in the Notch3 gene causing CADASIL. Ann Neurol. [Case Reports Research Support, Non-U.S. Gov’t]. 2000;47(3):388-91.
56.
Dong Y, Hassan A, Zhang Z, Huber D, Dalageorgou C, Markus HS. Yield of screening for CADASIL mutations in lacunar stroke and leukoaraiosis. Stroke. [Research Support, Non-U.S. Gov’t]. 2003;34(1):203–5.PubMedCrossRef
57.
Choi JC, Kang SY, Kang JH, Park JK. Intracerebral hemorrhages in CADASIL. Neurology. [Comparative Study Research Support, Non-U.S. Gov’t]. 2006;67(11):2042–4.PubMedCrossRef
58.
59.
Rolfs A, Bottcher T, Zschiesche M, Morris P, Winchester B, Bauer P, et al. Prevalence of Fabry disease in patients with cryptogenic stroke: a prospective study. Lancet. [Research Support, Non-U.S. Gov’t]. 2005;366(9499):1794–6.PubMedCrossRef
60.
Sims K, Politei J, Banikazemi M, Lee P. Stroke in Fabry disease frequently occurs before diagnosis and in the absence of other clinical events: natural history data from the Fabry Registry. Stroke. [Research Support, Non-U.S. Gov’t]. 2009;40(3):788–94.PubMedCrossRef
61.
Testai FD, Gorelick PB. Inherited metabolic disorders and stroke part 1: Fabry disease and mitochondrial myopathy, encephalopathy, lactic acidosis, and strokelike episodes. Arch Neurol. [Review]. 2010;67(1):19–24.PubMedCrossRef
62.
Buechner S, Moretti M, Burlina AP, Cei G, Manara R, Ricci R, et al. Central nervous system involvement in Anderson-Fabry disease: a clinical and MRI retrospective study. J Neurol Neurosurg Psychiatry. 2008;79(11):1249–54.PubMedCrossRef
63.
Brady RO, Murray GJ, Moore DF, Schiffmann R. Enzyme replacement therapy in Fabry disease. J Inherit Metab Dis. [Clinical Trial Controlled Clinical Trial Review]. 2001;24 Suppl 2:18–24; discussion 11-2.PubMedCrossRef
64.
Eng CM, Guffon N, Wilcox WR, Germain DP, Lee P, Waldek S, et al. Safety and efficacy of recombinant human alpha-galactosidase A- -replacement therapy in Fabry’s disease. N Engl J Med. [Clinical Trial Multicenter Study Randomized Controlled Trial Research Support, Non-U.S. Gov’t Research Support, U.S. Gov’t, P.H.S.]. 2001;345(1):9–16.PubMedCrossRef
65.
Alfadhel M, Sirrs S. Enzyme replacement therapy for Fabry disease: some answers but more questions. Ther Clin Risk Manag. 2011;7:69–82.PubMedCentralPubMed
66.
Jardim L, Vedolin L, Schwartz IV, Burin MG, Cecchin C, Kalakun L, et al. CNS involvement in Fabry disease: clinical and imaging studies before and after 12 months of enzyme replacement therapy. J Inherit Metab Dis. [Clinical Trial Research Support, Non-U.S. Gov’t]. 2004;27(2):229–40.PubMedCrossRef
67.
Wilcox WR, Banikazemi M, Guffon N, Waldek S, Lee P, Linthorst GE, et al. Long-term safety and efficacy of enzyme replacement therapy for Fabry disease. Am J Hum Genet. [Clinical Trial Clinical Trial, Phase III Comparative Study Randomized Controlled Trial Research Support, Non-U.S. Gov’t Research Support, U.S. Gov’t, P.H.S.]. 2004;75(1):65–74.PubMedCentralPubMedCrossRef
68.
Calabrese LH, Dodick DW, Schwedt TJ, Singhal AB. Narrative review: reversible cerebral vasoconstriction syndromes. Ann Intern Med. [Research Support, N.I.H., Extramural Review]. 2007;146(1):34–44.PubMedCrossRef
69.
Ducros A, Boukobza M, Porcher R, Sarov M, Valade D, Bousser MG. The clinical and radiological spectrum of reversible cerebral vasoconstriction syndrome. A prospective series of 67 patients. Brain. 2007;130(Pt 12):3091–101.
70.
Kurth T, Diener HC. Migraine and stroke: perspectives for stroke physicians. Stroke. [Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov’t Review]. 2012;43(12):3421–6.PubMedCrossRef
71.
Schurks M, Rist PM, Bigal ME, Buring JE, Lipton RB, Kurth T. Migraine and cardiovascular disease: systematic review and meta-analysis. Bmj. [Meta-Analysis Research Support, Non-U.S. Gov’t Review]. 2009;339:b3914.PubMedCentralPubMedCrossRef
72.
Spector JT, Kahn SR, Jones MR, Jayakumar M, Dalal D, Nazarian S. Migraine headache and ischemic stroke risk: an updated meta-analysis. Am J Med. [Meta-Analysis Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov’t]. 2010;123(7):612–24.PubMedCentralPubMedCrossRef
73.
Etminan M, Takkouche B, Isorna FC, Samii A. Risk of ischaemic stroke in people with migraine: systematic review and meta-analysis of observational studies. Bmj. [Meta-Analysis Research Support, Non-U.S. Gov’t Research Support, U.S. Gov’t, Non-P.H.S. Research Support, U.S. Gov’t, P.H.S. Review]. 2005;330(7482):63.PubMedCentralPubMedCrossRef
Metadaten
Titel
Ursache bleibt häufig unklar
Juveniler Schlaganfall
verfasst von
Prof. Dr. med. Klaus Jahn
Dr.med. univ. Maximilian Einhäupl
Publikationsdatum
07.03.2014
Verlag
Urban & Vogel
Erschienen in
DNP – Die Neurologie & Psychiatrie / Ausgabe 3/2014
Print ISSN: 2731-8168
Elektronische ISSN: 2731-8176
DOI
https://doi.org/10.1007/s15202-014-0630-3

Weitere Artikel der Ausgabe 3/2014

DNP - Der Neurologe & Psychiater 3/2014 Zur Ausgabe

Praxis konkret

Keimschleuder Tastatur?

Praxis konkret

Ärzte sind überzeugte QM-Täter

Praxis konkret_Abrechnungstipps

Kriterien der persönlichen Leistungserbringung

Ausstellung

Erfasst, verfolgt, vernichtet

Kurz gemeldet

Socke weist per App auf Fehlstellungen des Fußes hin

Kurz gemeldet

Neue Standards für das Risikomanagement

Neu in den Fachgebieten Neurologie und Psychiatrie

Chirurginnen und Chirurgen sind stark suizidgefährdet

07.05.2024 Suizid Nachrichten

Der belastende Arbeitsalltag wirkt sich negativ auf die psychische Gesundheit der Angehörigen ärztlicher Berufsgruppen aus. Chirurginnen und Chirurgen bilden da keine Ausnahme, im Gegenteil.

Ein Drittel der jungen Ärztinnen und Ärzte erwägt abzuwandern

07.05.2024 Medizinstudium Nachrichten

Extreme Arbeitsverdichtung und kaum Supervision: Dr. Andrea Martini, Sprecherin des Bündnisses Junge Ärztinnen und Ärzte (BJÄ) über den Frust des ärztlichen Nachwuchses und die Vorteile des Rucksack-Modells.

„Restriktion auf vier Wochen Therapie bei Schlaflosigkeit ist absurd!“

06.05.2024 Insomnie Nachrichten

Chronische Insomnie als eigenständiges Krankheitsbild ernst nehmen und adäquat nach dem aktuellen Forschungsstand behandeln: Das forderte der Schlafmediziner Dr. Dieter Kunz von der Berliner Charité beim Praxis Update.

Endlich: Zi zeigt, mit welchen PVS Praxen zufrieden sind

IT für Ärzte Nachrichten

Darauf haben viele Praxen gewartet: Das Zi hat eine Liste von Praxisverwaltungssystemen veröffentlicht, die von Nutzern positiv bewertet werden. Eine gute Grundlage für wechselwillige Ärztinnen und Psychotherapeuten.

Bildnachweise